Health Awareness Topics - May 2012
Visit the updated Hospital-Acquired Conditions
page for evidence-based resources available on the NGC Web site to assist users in the prevention of the CMS-identified hospital-acquired conditions.
The Guidelines International Network (G-I-N) Conference 2012
, will be held August 22-25, 2012
in Berlin, Germany. Registration
is now open.
U.S. Food and Drug Administration (FDA) Advisory
- April 26, 2012: Victrelis (boceprevir) and Ritonavir-Boosted Human Immunodeficiency Virus (HIV) Protease Inhibitor Drugs : FDA notified healthcare professionals that the Victrelis drug label has been revised to state that co-administration of Victrelis (boceprevir), a hepatitis C virus (HCV) protease inhibitor, along with certain ritonavir-boosted human immunodeficiency virus (HIV) protease inhibitors, is not recommended.
- April 20, 2012: Aliskiren-containing Medications : FDA notified healthcare professionals of possible risks when using blood pressure medicines containing aliskiren with other drugs called angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in patients with diabetes or kidney (renal) impairment. These drug combinations should not be used (are contraindicated) in patients with diabetes. In addition, avoid use of aliskiren with ARBs or ACEIs in patients with moderate to severe renal impairment. The labels for the aliskiren drugs are being updated based on preliminary data from a clinical trial
NGC's Sister Resources